Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis
PARIS & LONDON, July 06, 2026--Sofinnova Partners, a leading European life sciences venture capital firm, today announced that its portfolio company Myricx Bio ("Myricx") has reached agreement to be acquired by Novartis, for up to $1.5 billion including $1.1 billion cash upfront plus potential milestone payments. This marks Sofinnova Partners' seventh exit in three years.
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.